Dyslipidemia is a disruption in the amount of lipids in the blood.
Youths with type 1 diabetes, especially boys, already show early signs of cardiovascular disease by their teen-age years, according to researchers from the Keck School of Medicine of the University of Southern California and Childrens Hospital Los Angeles.
The reported results of a one-year phase III study in 1045 people with type 2 diabetes treated with rimonabant, the first in a new class of therapeutic agents called selective CB1 Blockers, were that rimonabant 20 mg significantly improved HbA1c (a measure of blood sugar control), dyslipidemia (abnormal levels of fat in the blood), and systolic blood pressure with a concomitant substantial reduction in abdominal obesity in people with type 2 diabetes treated with oral anti-diabetic medications and requiring further control.
A novel compound provides long-term lowering of blood glucose levels and improves plasma lipids (fats) that are often a problem in people with type 2 diabetes -- all in a once-daily pill, according to a report presented today at the American Diabetes Association's 65th Annual Scientific Sessions.
A new study designed to look at how well patients with high blood pressure and dyslipidemia (high cholesterol levels) coped with their medication, has discovered that within six months many patients fail to take blood pressure or cholesterol medication properly.
Therapy that includes medications to reduce high blood pressure and to lower lipid levels can reduce risk for heart disease, but within six months, more than a third of patients fail to take one or both medications as prescribed, according to a study in the May 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
One year after recommending that children should be checked for high blood pressure starting at age 3, medical experts reviewed additional supporting evidence for the pediatric blood pressure guidelines at the American Society of Hypertension's Twentieth Annual Meeting (ASH 2005).
Physical fitness and regular exercise reduces a major predictor of cardiovascular disease in adults with normal blood pressure or mild hypertension. Physical conditioning in the absence of medication is not, however, as advantageous to the more severe hypertensive patient, reported researchers at the American Society of Hypertension Twentieth Annual Scientific Meeting.
"The message is urgent about the importance of prevention of cardiovascular disease in childhood. Lifestyle modification with appropriate diet and exercise can reduce cardiovascular risk in children," said lead author Daniel L. Preud'Homme, M.D., associate professor of medicine at the Wright State University School of Medicine and director of the lipid clinic at The Children's Medical Center, both in Dayton, Ohio.
Young people with atherosclerotic lesions may be identified by a risk score calculated from coronary heart disease factors like obesity, sex, age, cholesterol, and smoking, according to an article in the April 25 issue of Archives of Internal Medicine.
Obesity may put African-Americans who have survived one stroke at risk for a second stroke by increasing their risk of hypertension (high blood pressure), diabetes and high cholesterol, according to an article in the March issue of Archives of Neurology, one of the JAMA/Archives journals.
Stroke survivors who stopped taking their prescribed daily aspirin tripled their risk of having another stroke within the month, according to research presented at the American Stroke Association's International Stroke Conference 2005.
A comparison of four popular diet plans finds that the key to losing weight may not be which diet plan a person picks, but sticking with the plan that is chosen, according to a study in the January 5 issue of JAMA.
The obesity rate among American workers of all ages grew from 20% to 29% over the past decade, leading to serious repercussions in the workplace and a demand for solutions, according to a new Pfizer Inc study published today in the Journal of Occupational and Environmental Medicine.
Obese patients who underwent surgical treatment for weight loss had significant reductions in the components of the metabolic syndrome one year after surgery, according to an article in the October issue of The Archives of Surgery.
Results from two new clinical trials show that patients with diabetes and metabolic syndrome who are treated with ezetimibe (EZETROL®) co-administered with a statin experience greater reductions in LDL (“bad”) cholesterol, compared to patients taking a statin alone.
Phase III clinical study comparing placebo to rimonabant, the first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) blockers, showed that overweight or obese people taking rimonabant 20mg once daily benefited from a significant reduction in their body weight
Having three or more traits of the metabolic syndrome significantly increases the risk of dying from coronary heart disease, cardiovascular disease or any other cause, according to a study in Circulation: Journal of the American Heart Association.
Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability and pharmacokinetics of GT389-255, a lipase inhibitor conjugated to a fat binding polymer for the treatment of obesity.
People who have high blood pressure are highly likely to also have untreated or insufficiently treated cholesterol problems that significantly increase their risk for heart attack and stroke
Results of three studies show the oral anti-diabetic agent ACTOS (R) (pioglitazone HCl), in combination with a sulfonylurea, metformin or insulin, resulted in triglyceride decreases and high-density lipoprotein (HDL) cholesterol increases that demonstrated statistically significant improvements from baseline.